Modality
Degrader
MOA
VEGFi
Target
MALT1
Pathway
Tau
Alzheimer'sIPFMCC
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
Nov 2021
→ Nov 2026
Phase 1Current
NCT05348002
774 pts·Alzheimer's
2021-11→2026-11·Active
774 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-093mo agoEnrollment Complete· IPF
2026-11-017mo awayInterim· Alzheimer's
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Active
Catalysts
Enrollment Complete
2026-01-09 · 3mo ago
IPF
Interim
2026-11-01 · 7mo away
Alzheimer's
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05348002 | Phase 1 | Alzheimer's | Active | 774 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |